Response of Cartilage Oligomeric Matrix Protein to Monoclonal Antibody Drugs in Patients with Rheumatoid Arthritis

Rheumatoid arthritis (RA), a chronic inflammatory disease characterized by an erosive synovitis, resulting in cartilage degeneration and joint destruction, is discussed. A better understanding of the immune and inflammatory mechanisms underlying joint damage, leading to disorganization of the joint...

Full description

Saved in:
Bibliographic Details
Published in:Laboratory medicine 2009-11, Vol.40 (11), p.645
Main Authors: Tampoia, Marilina, Brescia, Vincenzo, Falappone, Paola, Zucano, Antonietta, Scioscia, Crescenzo, Fontana, Antonietta, Iannone, Florenzo, Di Serio, Francesca, Lapadula, Giovanni
Format: Article
Language:English
Subjects:
Cytokines
Rheumatoid arthritis
Rheumatology
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Rheumatoid arthritis (RA), a chronic inflammatory disease characterized by an erosive synovitis, resulting in cartilage degeneration and joint destruction, is discussed. A better understanding of the immune and inflammatory mechanisms underlying joint damage, leading to disorganization of the joint structures and functional damage, in patients with RA is fundamental for the development of effective therapies. Advances in molecular technology techniques have contributed greatly to the creation of targeted treatments aimed at blocking the action of pro-inflammatory cytokines and more effective therapeutic strategies decreasing the incidence of both synovitis and joint damage in patients with RA being treated with disease monitoring antirheumatic drugs.
ISSN:0007-5027
DOI:10.1309/LMV894XJRQEJMKAB